Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes

Publication Date

2020

Journal Title

Clin Lymphoma Myeloma Leuk

Abstract

© 2020 Elsevier Inc. Ibrutinib-associated arthralgias/myalgias are a frequent adverse event that can occur late in the treatment course and are mostly grade 1 or 2. For patients with grade 1 or 2 arthralgias/myalgias, dose reductions can frequently mitigate the side effects and allow patients to continue on therapy, whereas the majority of patients with grade 3 toxicity ultimately discontinue therapy. Further study is needed to determine their pathogenesis in order to develop best practice management strategies.

Volume Number

20

Issue Number

7

Pages

438-444

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Hematology/Medical Oncology

PMID

32197990

DOI

10.1016/j.clml.2020.02.001

For the public and Northwell Health campuses

Share

COinS